Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2014-03-31 AGM Information
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Valberedningens förslag till styrelseledamöter m.m. i Vitrolife AB (publ)
AGM Information Classification · 98% confidence The document is a press release dated March 31, 2014, detailing the proposals made by the Nomination Committee (Valberedningen) for the upcoming Annual General Meeting (årsstämman) on May 5, 2014. The proposals concern the chairman of the meeting, the size and remuneration of the board, re-election of directors, appointment of the auditor, and the process for establishing the next nomination committee. These topics—proposals regarding board composition, director remuneration, and auditor appointment—are core components of the materials presented or voted upon at an Annual General Meeting (AGM). While it is a proposal *for* the AGM, it is directly related to the governance and structure discussed at that meeting. Since the document is a formal announcement of proposals intended for shareholder vote/discussion at the AGM, the most fitting category is AGM Information (AGM-R), as it contains the substance of what is typically presented or decided upon during that event.
2014-03-31 Swedish
Proposal of the Election Committee regarding members of the Board etc. for Vitrolife AB (publ)
AGM Information Classification · 98% confidence The document explicitly discusses proposals made by the 'Election Committee' for the upcoming 'Annual General Meeting' (AGM) scheduled for May 5, 2014. The proposals cover the election of the Chairman, the number of board members, board remuneration, re-election of current members, and the appointment of the auditor. This content directly relates to the agenda and preparatory materials for an AGM. Therefore, the most appropriate classification is AGM Information (AGM-R).
2014-03-31 English
Earnings Release 2013
Earnings Release Classification · 99% confidence The document is titled "bokslutskommuniké 2013" (Year-end report communication 2013) and contains detailed financial results for the fourth quarter and the full year (Helåret 2013). It includes key performance indicators (KPIs) like Net Sales (Nettoomsättning), Operating Profit (Rörelseresultat EBIT), Net Income (Nettoresultat), and Earnings Per Share (Resultat per aktie). This structure is characteristic of an Earnings Release (ER) or an Interim/Annual Report. Since it covers the full year and provides comprehensive financial statements and management commentary, it aligns closely with the content of an Annual Report (10-K) or a detailed Interim Report (IR). Given the Swedish context and the term 'bokslutskommuniké', which is often the initial release of the full-year results before the formal 10-K equivalent, it functions as a comprehensive financial report for the period. However, since the text is extensive (63,984 chars) and provides detailed breakdowns, it is more than just an 'Earnings Release' (ER). It is a comprehensive report covering the full fiscal year, making 'Interim / Quarterly Report' (IR) or 'Annual Report' (10-K) the closest fits. Since it covers the full year ('Helåret 2013') and is a detailed financial communication, it is best classified as an Interim/Quarterly Report (IR) if a specific annual report form (like 10-K) is not explicitly mentioned, as 'bokslutskommuniké' often serves as the primary annual financial disclosure in non-US contexts, similar to a comprehensive IR. FY 2013
2014-02-06 Swedish
Interim / Quarterly Report 2013
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Vitrolife AB covering the fourth quarter and the full year 2013. It includes detailed financial statements, key performance indicators, CEO commentary, and operational analysis. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis. It is not a 10-K as it is a quarterly/annual interim report for a Swedish company (not a US SEC 10-K filing). Therefore, it fits the definition of an Interim/Quarterly Report (IR). Q4 2013
2014-02-06 English
Vitrolife och Biolamina increase collaboration within stem cells
Share Issue/Capital Change Classification · 99% confidence The document is explicitly labeled as a "Press release" and details a strategic investment by Vitrolife in Biolamina, including a SEK 4 million investment for a 4.6% stake and future board representation. This type of announcement—a material corporate event update released to the public via press release—does not fit the specific definitions for financial reports (10-K, IR, ER), regulatory filings (like DIRS, MRQ), or meeting materials (AGM-R, DEF 14A). Since it is a general corporate announcement regarding financing/capital structure change (investment in another company), it most closely aligns with 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because a more specific category applies, and it is not an announcement of a report (RPA). The document length is moderate, suggesting it is the primary content, not just a notification.
2013-11-13 English
Vitrolife och Biolamina utökar samarbete inom stamceller
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled "Pressmeddelande" (Press Release) and announces an expansion of collaboration and an investment (4 MSEK for a 4.6% stake) by Vitrolife in Biolamina. This describes a specific corporate action related to financing, investment, and strategic partnership. This fits best under Capital/Financing Update (CAP), as it details a direct investment made by the company using its cash reserves, which is a capital structure/financing activity. It is not a full financial report (10-K, IR), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific transaction.
2013-11-13 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.